Mirum Pharmaceuticals, Inc. MIRM
92.49 USD +0.54 (+0.59%)
Regular-session close
93.50 +1.01 +1.09%
After hours · Nov 18, 4:23 PM ET
90.96 Day range 92.99
64.10 52-week range 128.57
- YTD
- +17.09%
- 1 year
- +28.12%
News
seekingalpha.com AMG TimesSquare Small Cap Growth Fund Q3 2026 Portfolio Activity During this quarter, AMG TimesSquare Small Cap Growth Fund outperformed the Russell 2000® Growth Index as the market rewarded the quality characteristics our process emphasizes. We benefited most…
businesswire.com Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).benzinga.com Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $194 Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $184 to $194.
zacks.com MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV Mirum's brelovitug marks a second phase III win in chronic HDV, bringing the company closer to a planned 2027 BLA filing with the FDA.
reuters.com Mirum's liver infection drug lowers virus levels in second late-stage study Mirum's liver infection drug lowers virus levels in second late-stage study
businesswire.com Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD.
defenseworld.net Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $1,800,000.00 in Stock Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) CEO Christopher Peetz sold 20,000 shares of the company's stock in a transaction on Wednesday, November 4th. The shares were sold at an…
defenseworld.net Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $1,800,000.00 in Stock Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) CEO Christopher Peetz sold 20,000 shares of the company's stock in a transaction on Wednesday, November 4th. The shares were sold at an…benzinga.com Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $140 Leerink Partners analyst Mani Foroohar maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $154 to $140.
businesswire.com GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing.benzinga.com CORRECTION: RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target RBC Capital analyst Lisa Walter reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and maintains $155 price target.
benzinga.com RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target RBC Capital analyst Luca Issi reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and maintains $155 price target.
benzinga.com Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $167 Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the price target from $144 to $167.
benzinga.com HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $202 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $200 to $202.
benzinga.com Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $160 Cantor Fitzgerald analyst Josh Schimmer maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $155 to $160.
seekingalpha.com Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call Transcript Mirum Pharmaceuticals, Inc. ( MIRM ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations…
marketbeat.com Mirum Pharmaceuticals Q3 Earnings Call Highlights Mirum Pharmaceuticals NASDAQ: MIRM reported third-quarter net product sales of $186 million and raised its full-year 2026 net product sales guidance to $715 million to $720 million, citing continued…
zacks.com Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings While the top- and bottom-line numbers for Mirum Pharmaceuticals (MIRM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its…
zacks.com Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to earnings of $0.05 per share a year ago.
benzinga.com Mirum Pharmaceuticals Q3 2026 Earnings Call Transcript Mirum Pharmaceuticals (NASDAQ:MIRM) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Mirum Pharmaceuticals Raises FY2026 Sales Guidance from $680.000M-$700.000M to $715.000M-$720.000M vs $698.093M Est Mirum Pharmaceuticals (NASDAQ:MIRM) raises FY2026 sales outlook from $680.000 million-$700.000 million to $715.000 million-$720.000 million vs $698.093 million estimate.
benzinga.com Mirum Pharmaceuticals Q3 EPS $(0.87) Misses $(0.51) Estimate, Sales $185.721M Beat $178.078M Estimate Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.51) by 70.59 percent. This is a 1840 percent decrease over…
businesswire.com Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update.
businesswire.com Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026 FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026.
zacks.com Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.benzinga.com Mirum Pharmaceuticals Announces Results From Cohort 2 Of Pivotal PROGRESS Study Of ATEBRIOZ - Zilurgisertib reduced total HO lesion volume and improved clinician-assessed joint mobility; no zilurgisertib-treated patients developed new HO lesions- Mirum plans to submit an sNDA in H1 2027 to…
businesswire.com Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Patients Aged 6 tobenzinga.com TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $145 TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $140 to $145.
defenseworld.net Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Rated “Moderate Buy” by Wall Street Brokerages Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fifteen ratings firms that are presently covering the company,…
defenseworld.net Head-To-Head Survey: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Mirum Pharmaceuticals (NASDAQ:MIRM) Mirum Pharmaceuticals (NASDAQ: MIRM - Get Free Report) and Kiniksa Pharmaceuticals International (NASDAQ: KNSA - Get Free Report) are both mid-cap healthcare companies, but which is the superior…
businesswire.com Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
zacks.com Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases MIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.
